MSH2 and breast carcinoma: All patients underwent a 37 NGS gene panel as part of standard of care investigation, which revealed one patient with a pathogenic variant in MEN1, one patient with a pathogenic PALB2 variant, one patient with a likely pathogenic variant in APC and another patient with a pathogenic variant in NTHL1. Five VUS were also identified in ATM, FANCM, MLH1, STK11 and MSH2. Given the pervasiveness of gene panel testing in breast cancer patients, our findings suggest that gene panel testing should be conducted on patients with a combination of breast cancer and NET regardless of family history.